Abstract: The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a local anesthetic in the form of a clear oily solution and methods for making same. The formulations can be administered by infiltration into an incision, or by injection.

Abstract: A non-fluoride containing toothpaste enriched with at least one dietary supplement. The non-fluoride containing toothpaste comprising a dentally acceptable oral vehicle containing a sufficient amount of thickening agent to impart a pasty consistency; and at least one dietary supplement wherein a serving size portion of the non-fluoride containing toothpaste contains more than about 2 percent of the reference daily intake (RDI) of the dietary supplement.

Abstract: This invention relates to a solution formulation containing a tiotropium salt, 12-20% ethanol, 0.1-1.5% of water, 0.05-0.10% citric acid (or other organic acid) and an HFA propellant, wherein the percentages are percentages by weight based on the total weight of the formulation. The invention also provides a pMDI comprising a canister containing the formulation.

Abstract: A non-adhering oral tape, film or strip home oral care composition includes a cleansing effective amount of a teeth cleaning agent and a fluoridating effective amount of a fluoridating agent; to methods of forming or using these non-adhering oral tapes, films or strips, and particularly to non-adhering oral tapes, films or strips containing precise dosage amounts of fluoride. Precision fluoride dosage can help mitigate the inherent problems of fluoride over dosage associated with standard dentifrice formulations. The present disclosure is also directed to kits for home use containing these non-adhering oral tapes, films or strips.

Abstract: The invention provides antibacterial combinations of essential oils comprising bisabolol and one or more essential oils selected from citral, carvacrol, oregano extract, and rosemary, or comprising carvacrol and one or more essential oils selected from bisabolol, thymol, and rosemary, together with compositions, e.g., oral care compositions, comprising these combinations, and uses therefore.

Abstract: The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.

Abstract: The invention relates to triterpenes and triterpene glycosides of the formula (I) and/or physiologically acceptable salts thereof, preferably naturally occurring triterpenes and triterpene glycosides from Mycetia balansae and/or physiologically acceptable salts thereof and orally consumable formulations comprising one or a plurality of these triterpenes and triterpene glycosides and/or physiologically acceptable salts thereof. The invention further relates to the use of these triterpenes and triterpene glycosides and/or physiologically acceptable salts thereof, preferably an extract of Mycetia balansae, for generating a sweet impression in an orally consumable formulation or for reinforcing the sweet impression of an orally consumable formulation comprising at least one further, preferably naturally occurring, sweet-tasting substance.

Abstract: The present invention relates generally to oral care compositions, and more specifically to oral care compositions suitable for cleaning the oral cavity. Methods of use are also disclosed.

Abstract: Substance mixtures are proposed, comprising (a) terpenes, (b) propane-1,3-diol, and optionally (c) active substances selected from the group consisting of (c1) rebaudiosides or plant extracts comprising them, (c2) steviosides or plant extracts comprising them, (c3) monatin, (c4) naringin, (c5) chalcones and hydrochalcones, (c6) mogrosides or plant extracts comprising them, (c7) rubusosides or plant extracts comprising them, and (c8) glycyrrhizic acid or plant extracts comprising it.

Abstract: The invention relates to a method for the production of highly stable aqueous dispersions of phytosterols, phytostanols and derivatives thereof, which allows the use of a wide range of emulsifiers in relatively small concentrations in relation to the phytosterols and which allows the preparation of dispersions with high concentrations of phytosterols. Said dispersions are obtained using a method in which one or more phytosterols, an aqueous medium and one or more emulsifiers are dispersed in a disperser at a temperature of at least 140° C. in order to obtain an emulsion and the resulting emulsion is subsequently cooled in order to obtain a dispersion of sterols in an aqueous medium.

Abstract: The present invention is to providing a new preparation including complex of a medical compound with lutein, astaxanthin and antioxidant. The new preparation includes stabilized liposome preparation, sustained release preparation and polymeric micelles preparation which used as delivery systems for lutein, astaxanthin and antioxidant. The new preparation significantly increases bioavailability of lutein and astaxanthin and uses for treatment and prevention of eyes and other disease.

Abstract: The invention is antibacterial mouthwash which does not have any side effects as it does not have toxicity in cellular level during the fight against oral cavity diseases and which is used for eliminating microbial dental plaques.

Abstract: The present disclosure provides compositions and methods useful for treating influenza. As described herein, provided compositions and methods are based on the development of certain compositions that include an influenza virus hemagglutinin antigen in combination with lipid vesicles that include a non-ionic surfactant (NISVs) and optionally an adjuvant. In certain embodiments, provided compositions remain potent even when they are not stored in a standard cold-chain system (i.e., they are thermostable).

Abstract: A molecule mixture comprising an amphipathic molecule of type A, which has an overall positive charge in the hydrophilic region, an amphipathic molecule of type B and a polyphenol C, the method for producing the molecule mixture, and the use thereof. The molecules of types A and B are present at a molecular ratio of A:B of 1(±0.2):1(±0.2) mol/mol. A method for producing the mixture and the use is also disclosed.

Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.

Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 7 hours or longer, followed by an ascending release rate. When administered at night the composition provides early morning improvement in symptoms of ADHD and sustained improvement over a period of at least 12 hours.

Abstract: The disclosure relates to novel dendrimer conjugates and the methods of synthesizing the same, as well as systems and methods utilizing the dendrimer conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease diagnosis and/or therapy, etc.))).

Abstract: The invention solves the problem of the practical realization of an effective prophylactic composition which uses available and safe components and which can be recommended for preventing the growth of candidiasis of the skin and/or mucous membranes in humans in the following risk group: sufferers of diabetes mellitus, people with blood diseases, immune deficiency and other serious pathologies, patents after a course of hormone therapy, antibiotic treatment or chemotherapy, as well as for babies and pregnant women; and for people using tooth implants. The composition for the prophylaxis of candidiasis comprises active components, with the active components used being xylitol in a quantity of 0.3-20.0% by mass and sodium or potassium alginate or a mixture thereof in a quantity of 0.01-2.0% by mass, as well as inert components.

Abstract: In certain embodiments, the present invention relates to compounds, compositions, and methods for disrupting biofilms. In some embodiments, the compounds and compositions comprise unsaturated long chain alcohols and/or aldehydes, or combinations of such compounds. In further embodiments, the present invention contains therapeutic actives to help reduce and/or eradicate the bacteria in the biofilm once the film is disrupted.

Abstract: A method of making dietary supplement compositions includes generating an aqueous phase, generating an oil phase, performing a first homogenizing step by mixing the aqueous and oil phases, adding reduced glutathione to the aqueous-oil composition and performing a second homogenizing step by mixing the aqueous-oil composition and reduced glutathione, adding a first flavor to the aqueous-oil-glutathione composition, performing a third homogenizing step by mixing the aqueous-oil-glutathione composition and the first flavor, adding xanthan gum dispersed with glycerin to the aqueous-oil-glutathione-first-flavor composition and performing a fourth homogenizing step by mixing the aqueous-oil-glutathione-first-flavor composition and xanthan gum; adding a second flavor to the aqueous-oil-glutathione-first-flavor-xanthan composition and performing a fifth homogenizing step by mixing the aqueous-oil-glutathione-first-flavor-xanthan composition and the second flavor so as to form a dietary supplement composition.